| Property | Value |
|---|
|
?:abstract
|
-
Biological therapy is the breakthrough in the management of spectrum of various diseases It also concerns asthma therapy The data regarding the role of biologics in the treatment strategy of severe asthma are presented The overview on how mediators of type 2 inflammation drives the pathology of the disease is given It justifies the biological treatment options approved The development of treatment strategy targeting non-type 2 inflammation is also highlighted The data regarding the risk and safety of biologics are discussed Document includes the featured rules of the classification of patients with severe asthma to this reliable and efficient therapy The outlook how to perceive the safety of biologics in the time of COVID-19 epidemic is also given
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
-
Alergologia_Polska-Polish_Journal_of_Allergology
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Biological therapy of asthma - position statement of Polish Allergology Society (PTA) and Polish Society of Lung Diseases (PTChP)
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}